Nasdaq

MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?

Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
News Medical

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
Business Insider

Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive disorder had fewer psychiatric hospitalizations after taking ...
News Medical

GeneSight test-guided treatment leads to faster remission and response in patients with depression

Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
Seeking Alpha

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a ...
Seeking Alpha

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...
Business Insider

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the ...
Fox 5 San Diego

More than half say genetic testing for mental health medications could reduce concerns

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet ...
Psychology Today

Wellpoint | Amerigroup Psychiatrists in Indiana

Your treatment here goes beyond traditional psychiatry — including GeneSight testing to match medications to your unique DNA. No traditional trail-and-error process ...